Marker Therapeutics (NASDAQ:MRKR) Rating Increased to Strong-Buy at Brookline Capital Management

Marker Therapeutics (NASDAQ:MRKR) was upgraded by analysts at Brookline Capital Management to a “strong-buy” rating in a research note issued to investors on Monday,Zacks.com reports.

Separately, LADENBURG THALM/SH SH lifted their target price on shares of Marker Therapeutics from $11.00 to $19.00 and gave the company a “buy” rating in a research report on Monday, October 21st.

Marker Therapeutics Stock Performance

MRKR opened at $1.55 on Monday. Marker Therapeutics has a one year low of $1.55 and a one year high of $5.99. The company has a fifty day moving average price of $2.92 and a 200-day moving average price of $3.25.

Insiders Place Their Bets

In other Marker Therapeutics news, Director Steve Elms bought 11,085 shares of the firm’s stock in a transaction that occurred on Monday, December 23rd. The shares were bought at an average price of $3.20 per share, for a total transaction of $35,472.00. Following the transaction, the director now directly owns 325,370 shares in the company, valued at $1,041,184. This trade represents a 3.53 % increase in their ownership of the stock. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Also, major shareholder Enterprise Associates 16 New purchased 554,250 shares of the stock in a transaction on Monday, December 23rd. The stock was acquired at an average cost of $3.20 per share, with a total value of $1,773,600.00. Following the completion of the purchase, the insider now directly owns 1,625,678 shares of the company’s stock, valued at $5,202,169.60. The trade was a 51.73 % increase in their ownership of the stock. The disclosure for this purchase can be found here. Corporate insiders own 17.35% of the company’s stock.

Institutional Inflows and Outflows

An institutional investor recently bought a new position in Marker Therapeutics stock. Invst LLC purchased a new position in Marker Therapeutics, Inc. (NASDAQ:MRKR) during the third quarter, according to its most recent disclosure with the Securities and Exchange Commission. The fund purchased 20,000 shares of the company’s stock, valued at approximately $56,000. Invst LLC owned 0.22% of Marker Therapeutics at the end of the most recent reporting period. Institutional investors and hedge funds own 22.39% of the company’s stock.

About Marker Therapeutics

Marker Therapeutics, Inc, a clinical-stage immuno-oncology company, engages in the development and commercialization of novel T cell-based immunotherapies for the treatment of hematological malignancies and solid tumor indications. Its multi tumor associated antigen-specific T cell technology is based on the manufacture of non-engineered tumor-specific T cells that recognize multiple tumor-associated antigens.